# GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）

> **NCT06988592** · — · RECRUITING · sponsor: **Fudan University** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Biliary Tract Cancer

## Interventions

- **DRUG:** GemCis plus PD-1/PD-L1 inhibitor

## Key facts

- **NCT ID:** NCT06988592
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-23
- **Primary completion:** 2027-05-18
- **Final completion:** 2027-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06988592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06988592, "GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06988592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*